Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With Australia's CSL
This article was originally published in PharmAsia News
Executive Summary
Merck took its time coming back into the flu vaccine field, but the expansion of world suppliers of vaccines brought a very well-suited partner to its doorstep